39 results about "Drug resistant tuberculosis" patented technology

The invention relates to a method adopting double-label probe detection and melting curve analysis for diagnosing the infection of multi-drug resistant mycobacterium tuberculosis and a kit which utilizes the method to detect multiple gene mutations related to drug resistant tuberculosis at the same time, and the invention belongs to the life science and biological technical field. The kit of the invention contains a primer designed for multiple gene mutations related to drug resistant, a double-label oligonucleotide probe capable of detecting multiple common gene mutation sites related to drug resistant tuberculosis and a DNA polymerases with heat stability and without 5' nuclease activity, and the kit can be used to detect at least 16 common gene mutation sites related to drug resistant tuberculosis under proper PCR reaction conditions. The detection method and kit of the invention can be used in the early diagnosis of multi-drug resistant tuberculosis and overcome the problems of the existing technology that the detection time is long, a great deal of manpower and large material resources are needed, the detection cost is high, etc.

The invention relates to an artemisinin pharmaceutical composition, and particularly relates to a composition of nano chitosan artemisinin and antituberculosis drugs, used for treating drug-resistant tuberculosis. The pharmaceutical composition comprises the following effective components: the antituberculosis drugs, the nano chitosan artemisinin, three nano chitosan artemisinin derivatives or artemisinin and a derivative of artemisinin, wherein the nano chitosan artemisinin is prepared from the following ingredients by weight percent: 40-805 of artemisinin or artemisinin derivatives, 1-5% of polyvinyl pyrrolidone and 15-50% of nano chitosan. Artemisinin drugs, the nano chitosan artemisinin and derivatives, and the antituberculosis drugs are used as the pharmaceutical composition, so that drug-resistant tubercle bacillus can be inhibited and killed; and the pharmaceutical composition has a prominent curative effect on the drug-resistant tuberculosis.

The invention provides a fusion protein and its use in treatment on tuberculosis. The fusion protein can realize targeting and specific induction of apoptosis of macrophages with the function of phagocytosis of tubercle bacillus, can kill intracellular bacterial parasite and does not induce bacterial drug resistance. The fusion protein plays an important role in treatment on drug-resistant tuberculosis.

The invention belongs to the technical field of pharmaceutical chemistry, and especially relates to use of compound AG120 or pharmaceutically acceptable salt thereof in preparation of drug for prevention or treatment of tuberculosis, and a pharmaceutical composition for preventing or treating tuberculosis. The compound AG120 can effectively inhibit the infection of tuberculosis bacillus, thereby providing effective drug support for the prevention or treatment of tuberculosis. Therefore, the present invention discloses compound AG120 which can be used as a lead compound for preventing or treating tuberculosis, and has the activity of anti-tuberculosis bacteria and drug-resistant tuberculosis bacteria, and is particularly suitable for preventing or treating tuberculosis, thus having wide clinical application prospect and great market potential.

Disclosed in the invention are a pyrazolo[1,5-a]pyridine compound with the structural features as shown in formula (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (MIC) of the compounds is lower than 0.1 μg / mL and partially achieves 0.01 μg / mL, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (MDR-TB) strains. In an in vivo experiment, the pyrazolo[1,5-a]pyridine compounds of the present invention can effectively scavenge the infectious dose of H37Ra in a mouse body at 20mg / kg / d doses, thereby being a new type of antituberculosis compound.

The invention relates to a method adopting double-label probe detection and melting curve analysis for diagnosing the infection of multi-drug resistant mycobacterium tuberculosis and a kit which utilizes the method to detect multiple gene mutations related to drug resistant tuberculosis at the same time, and the invention belongs to the life science and biological technical field. The kit of the invention contains a primer designed for multiple gene mutations related to drug resistant, a double-label oligonucleotide probe capable of detecting multiple common gene mutation sites related to drug resistant tuberculosis and a DNA polymerases with heat stability and without 5' nuclease activity, and the kit can be used to detect at least 16 common gene mutation sites related to drug resistant tuberculosis under proper PCR reaction conditions. The detection method and kit of the invention can be used in the early diagnosis of multi-drug resistant tuberculosis and overcome the problems of the existing technology that the detection time is long, a great deal of manpower and large material resources are needed, the detection cost is high, etc.

The present invention is a medicine for treating pulmonary tuberculosis, which is characterized in that the raw materials for making active ingredients are composed of (1) garlic; (2) salt and / or mint. The invention also discloses a preparation method of a drug for treating pulmonary tuberculosis and a use method thereof. The medicine of the invention is simple in formula, low in cost and remarkable in curative effect. It has been proved by clinical trials that the average total effective rate can reach more than 98%, has miraculous effect on the treatment of drug-resistant pulmonary tuberculosis, and has no toxic and side effects on the human body. The method is very simple. The drug directly acts on the human lungs, and the effect is quick. It also has the effect of preventing secondary disease for those who have a history of tuberculosis. The medicament of the present invention can be used for the treatment of various types of pulmonary tuberculosis diseases, and can also be used for the treatment of other pulmonary diseases and upper respiratory tract diseases.

The invention relates to a method for preparing a mycobecterium tuberculosis gene vaccine used for curing drug-resistant tuberculosis, and is characterized in that the mycobacterium tuberculosis gene vaccine against the drug-resistant tuberculosis clones a coding gene sequence of the mycobacterium tuberculosis Ag85A to the eukaryotic expression vector pVAX1, or clones coding gene sequences of theAg85A and the ESAT6 together to the eukaryotic expression vector pVAX1 to form the ESAT6-Ag85A chimeric gene vaccine. Separated immunity or combined chemotherapy can obviously relieve pathology change in lungs of mice with drug-resistant tuberculosis and can obviously reduce bacteria numbers in lungs and spleens of little mice.

The present invention discloses ribosomal protein S1(RpsA) with structural N-(thiophene-2)amide derivatives (formula (1)) antagonistic ribosome 30S small subunits, and the protein can effectively inhibit the growth of Mycobacterium tuberculosis and pyrazinamide-resistant Mycobacterium tuberculosis and can be used to prepare drugs for treating pyrazinamide-resistant tuberculosis and tuberculosis.

The invention belongs to the technical field of medicine, and specifically relates to a compound prescription composed of traditional Chinese medicines mulberry and mistletoe, a series of compound prescriptions derived from the combination of one or more other traditional Chinese medicines and the application thereof. These compounds have the functions of anti-tuberculosis, anti-inflammation, anti-infection, clearing the lungs and reducing phlegm, relieving cough and hemostasis, strengthening the heart and nourishing the lungs, and regulating immunity. They can be used alone or in combination with chemotherapy drugs and antibacterial drugs to treat tuberculosis, pulmonary heart disease, Pneumonia, acute and chronic bronchitis and other respiratory infectious diseases and syndromes are especially suitable for the treatment of drug-resistant and drug-resistant tuberculosis, which can alleviate and reduce the toxicity caused by chemotherapy and improve the therapeutic effect.

The invention discloses a catechu extract composition for resisting tubercle bacillus, a preparation method of the catechu extract composition, a pharmaceutical preparation containing the catechu extract composition, and application of the catechu extract composition. The catechu extract composition contains a flavanoid compound of which the purity is more than 50%, and the flavanoid compound takes catechin and / or epicatechin as main components. The main structural formulas (I) and (II) of the flavanoid compound are shown in the specifications, wherein R1, R2, R3, R4 and R5 are respectively and independently selected from hydrogen, C1-C6 alkyl, beta-D-glucopyranesyl, SO3 or PO3. By adopting a chromatographic process for refining and purifying the catechu extract composition disclosed by the invention, the effective content is as high as 99.5%. The catechu extract composition and the pharmaceutical composition thereof have excellent effects on improving or treating pulmonary tuberculosis, treating ulcerative bone tuberculosis and AIDS (Acquired Immune Deficiency Syndrome) complicated by tuberculosis, treating drug resistant tuberculosis, and especially treating drug resistant tuberculosis and AIDS complicated by tuberculosis.

Tricyclic derivatives of formula (1) for antimicrobial agents, wherein R1 can be alkylsulfonate or sulfonamide. The derivatives are optionally substituted, wherein R2 is hydrogen, halogen, substituted alkyl, thioether or acetyl; Y can be N or C; X can be S, SO, SO2, N, O, CH2, C(O), CO2, NHCO, and Ring B is a 6-, 7-, or 8-membered cycloalkyl ring. The tricyclic derivatives, such as phenothiazine derivatives, can be used to treat pulmonary tuberculosis, especially drug-sensitive and drug-resistant pulmonary tuberculosis. The derivatives of the present invention may be used alone or in combination with known anti-tuberculosis drugs such as ethionamide and ethambutol, and the combination may be administered as a single dose or as two separate doses . The tricyclic derivatives can also be used in the manufacture of drugs for the treatment of tuberculosis.

This invention concerns the use of mefloquine in relation to Mycobacterium tuberculosis. This invention also concerns the combination of mefloquine with drugs used in first and second choice treatment of tuberculosis, achieving a reduction in the treatment period of tuberculosis (TB) and the treatment of multi-drug resistant tuberculosis (MDR-TB).

The invention discloses application of a tsaoko amomum fruit extract, and provides application of a tsaoko amomum fruit alcohol extract to preparation of drugs for drug-resistant tuberculosis, and application of the tsaoko amomum fruit alcohol extract to preparation of drugs for inhibiting drug-resistant mycobacterium tuberculosis. A Soxhlet extraction method is adopted, ethyl alcohol with the concentration being 80-100% is taken as a solvent, then tsaoko amomum fruit is heated, subjected to reflux extraction, filtered, concentrated, frozen and dried, and thus the tsaoko amomum fruit alcohol extract is obtained. Through experiments, it is proved that the tsaoko amomum fruit alcohol extract has the quite high antituberculous effect on mycobacterium tuberculosis, especially multiple-drug-resistant mycobacterium tuberculosis, in addition, through the cytotoxicity evaluation result of the tsaoko amomum fruit alcohol extract, it is proved that the tsaoko amomum fruit alcohol extract has noobvious cytotoxicity to human embryonic lung fibroblast MRC-5 when the concentration of the tsaoko amomum fruit alcohol extract is not greater than 250 [mu]g / mL, and therefore, the tsaoko amomum fruitextract is of important significance on development of drugs resisting tubercle bacillus, especially drug-resistant tubercle bacillus.

The invention provides antibacterial compounds comprising an oligonucleotide having a sequence complementary to a translation initiation region of an mRNA encoding a mycolyl transferase of Mycobacterum tuberculosis selected from protein 30, 32A and 32B, and further having 5′ and 3′ palindromic hairpin-forming sequences, said compound being covalently linked to a protein synthesis inhibiting antibiotic via a linker. The invention further provides pharmaceutical formulations of such compounds and methods of use thereof for treating tuberculosis. Other diseases may similarly be treated by tethering and antibiotic which targets a ribosomal protein to an antisense oligonucleotide complementary to an mRNA involved in the disease.

The present invention is directed to 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and / or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drug resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy) are also disclosed. These compositions are useful against an autophagy mediated disease state and / or condition), especially an autophagy mediated disease state and / or condition which occurs in the lungs.

The invention belongs to the technical field of biological agents and discloses a novel biological agent for treating drug resistant tuberculosis and a preparation method thereof. The novel biologicalagent for treating drug resistant tuberculosis is a tuberculosis specific lymphocyte and is prepared by utilizing IL-1 alpha, IL-2, a CD3 monoclonal antibody and tuberculosis specific antigens (CFP10, ESAT6). Compared with the conventional tuberculosis treatment method, the novel biological agent disclosed by the invention is reported for the first time at home and abroad, and obvious curative effects are achieved when patients with pulmonary tuberculosis are treated by utilizing lymphocytes cultured in vitro. For patients subjected to cell therapy, the number of lymphocytes in peripheral blood is obviously increased, the sputum examination result is rapidly turned to be negative, pulmonary shadow is rapidly absorbed, the course of disease is shortened, the mental state is improved, and the appetite and weight are increased. The living quality of the patients in anti-tuberculosis therapy is obviously improved.

The invention discloses RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme for targeted therapy of tuberculosis. A nucleotide sequence is one of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3. The invention simultaneously discloses use of the RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme for targeted therapy of tuberculosis in a drug for treating latent infection caused by L-type mycobacterium tuberculosis. By adopting the RelA cut and TLR7 active sequence modified locked nucleic acid deoxyribozyme, the advantages of effects of gene therapy and immunological therapy are integrated; and the therapeutical effect is played specifically aiming at drug-resistant tuberculosis of infection in the body, especially the L-type mycobacterium tuberculosis.